Joachim Eeckhout, Author at Labiotech.eu

About

Founder & Managing Director at Labiotech.eu. While I was studying biotechnology in Paris, I got frustrated by the lack of digital media available for the industry and decided to fix it! I launched Labiotech.eu in 2014 and grew it to the largest community for biotech professionals in Europe! Other than biotech news, I’m also a heavy reader of Sci-Fi and Fantasy.

Articles by Joachim Eeckhout

News and Trends 20 May 2015

Danish Startup Biosyntia grabs €1.7M to Inject Synthetic Biology into Vitamin Production

Biosyntia is a Danish start-up company in the synthetic biology field. The company aims at replacing chemical-based vitamin production by sustainable and fermentation-based processes. Yesterday, during our Denmark Biotech Tour, we met Andreas Laustsen, one of Biosyntia‘ founders who told us that the company has just raised €1,7M from Novo Seeds. The startup was founded in 2012 by […]

May 20, 2015 - 2 minutesmins - By Joachim Eeckhout

News and Trends 19 May 2015

Boehringer kindles NASH treatments with Pharmaxis’ drug acquisition

Does NASH mean anything to you? You should be vigilant about this market as it could be the source of next major blockbusters. This new and latest acquisition by Boehringer, is yet another sign of the growing interest for NASH treatments, already chased by companies such as Intercept, Genfit or Gilead. NASH, or non-alcoholic steatohepatitis, is regarded as […]

May 19, 2015 - 4 minutesmins - By Joachim Eeckhout

News and Trends 15 May 2015

European companies present their cancer treatment solutions in the USA

Each year, the American Society of Clinical Oncology gathers the cancer therapy developers during five days to present their latest results. Roche seems to be the European winner of this roundup, with amazing results of alectinib in non-small cell lung cancer (NSCLC). Roche’s investigational medicine alectinib shrank tumors in nearly half of patients suffering from this […]

May 15, 2015 - 3 minutesmins - By Joachim Eeckhout

News and Trends 15 May 2015

Ablynx gets tangled up in partnerships with Big Pharma companies

The Belgium-based company is leading more than 20 pre-clinical and clinical programmes with several partners to put the Nanobody technology on the market. Companies such as AbbVie, Boehringer Ingelheim, Eddingpharm, Merck & Co, Merck Serono and Novartis are part of Ablynx’s dream team. Ablynx is a biotech company developing Nanobodies. Nanobody technology was originally developed […]

May 15, 2015 - 3 minutesmins - By Joachim Eeckhout

News and Trends 15 May 2015

European Union supports Bavarian Nordic to cure Ebola

Bavarian Nordic has been granted €50M loan from the European Investment Bank (EIB) to support the companies’ pipeline including novel vaccines against Ebola and other infectious diseases as well as cancer immunotherapies. The loan is a three-to-five year bullet loan with fixed or variable interest payment. Bavarian Nordic has up to 18 months to draw […]

May 15, 2015 - 2 minutesmins - By Joachim Eeckhout

News and Trends 13 May 2015

Axovant banks on GSK’s scrapped project

Last December, Axovant acquired for €4.5M ($5 million) the drug candidate SB742457 from GlaxoSmithKline. Four months later, the company announced its initial public offering to raise up to €154M ($173 million). Why is this newly funded company betting on the leftovers of the Big Pharma? The drug candidate SB742457 is a selective 5-HT6 receptor antagonist, developed as an oral […]

May 13, 2015 - 3 minutesmins - By Joachim Eeckhout

News and Trends 11 May 2015

Are AbbVie and J&J already fighting to acquire Galapagos’ pipeline?

Ten years ago, Galapagos completed its initial public offering with a dual listing in Amsterdam and Brussels. Since then, Galapagos has grown, from 70 to more than 400 employees and from €70M to around €1.2Bn in market capitalization. Galapagos recently reported positive results with its JAK1 inhibitor in nearly 900 rheumatoid arthritis patients worldwide, triggering the interest […]

May 11, 2015 - 2 minutesmins - By Joachim Eeckhout

News and Trends 8 May 2015

GSK sparks off the Gene Therapy resurgence

GlaxoSmithKline has become the first big pharma company to file a gene therapy approval case to the European Medicines Agency (EMA). The therapy, developed in collaboration with San Raffaele Hospital and the Telethon Foundation in Italy, is designed to cure a disease called adenosine deaminase (ADA) deficiency, which causes severe combined immunodeficiency syndrome, lead to serious infections and, ultimately, death. ADA […]

May 8, 2015 - 4 minutesmins - By Joachim Eeckhout

News and Trends 7 May 2015

Versantis, using liposomes technology to detoxify the body

What happens when your liver stops working? The toxins your body continuously produces will no longer be eliminated, transforming your own body in a remarkable poison factory. This problem, in reality, is quite common. Liver diseases affect more than 30 million Europeans, and kill more people than both diabetes and road accidents combined! Versantis, a Swiss based biotech […]

May 7, 2015 - 5 minutesmins - By Joachim Eeckhout

News and Trends 6 May 2015

Hello Tomorrow Challenge, a preview of the startup competition

Hello Tomorrow’s main goal is to create bridges between scientists, investors and entrepreneurs in all major technological fields. On 9th of April 2015, the team of Hello Tomorrow invited us to attend to their press conference given at the Ministry of Foreign Affairs in Paris. In April 2014, after three long years of preparation, the “First day […]

May 6, 2015 - 3 minutesmins - By Joachim Eeckhout

News and Trends 3 May 2015

After its IPO, Poxel maintains its promise to develop a new Type 2 diabetes drug

Poxel continues to interest the market after its successful IPO in February 2015, where it has raised approximately €27M with an incredible jump of +100% on its third day as a public company. Imeglimin, its lead candidate, is a Type 2 diabetes treatment (licensed by Merck Serono) on the launch of Phase III. This innovative compound is […]

May 3, 2015 - 3 minutesmins - By Joachim Eeckhout

News and Trends 2 May 2015

Newron raised new funds to continue the development of Neurological therapies

Newron Pharmaceuticals, a public company focused on novel Central Nervous System (CNS) and pain therapies, announces that it has completed a capital increase of approximately €23.2M (CHF24.3 million). This fundraising will be used to accelerate the development of Newron’s pipeline of innovative CNS therapeutics: The company priority seems to be on NW-3509, an add-on therapy for schizophrenia, for […]

May 2, 2015 - 2 minutesmins - By Joachim Eeckhout

Knowledge hub

Categories

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Joachim Eeckhout

About

Articles by Joachim Eeckhout

Danish Startup Biosyntia grabs €1.7M to Inject Synthetic Biology into Vitamin Production

Boehringer kindles NASH treatments with Pharmaxis’ drug acquisition

European companies present their cancer treatment solutions in the USA

Ablynx gets tangled up in partnerships with Big Pharma companies

European Union supports Bavarian Nordic to cure Ebola

Axovant banks on GSK’s scrapped project

Are AbbVie and J&J already fighting to acquire Galapagos’ pipeline?

GSK sparks off the Gene Therapy resurgence

Versantis, using liposomes technology to detoxify the body

Hello Tomorrow Challenge, a preview of the startup competition

After its IPO, Poxel maintains its promise to develop a new Type 2 diabetes drug

Newron raised new funds to continue the development of Neurological therapies

Subscribe to our newsletter to get the latest biotech news!

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

About

Articles by Joachim Eeckhout

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!